



Atty. Dkt. No.: 05346678296

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tadamitsu KISHIMOTO, *et al.*

Title: CHRONIC RHEUMATOID ARTHRITIS THERAPY CONTAINING
ANTAGONIST AS EFFECTIVE COMPONENT

Appl. No.: U.S. Serial No. 09/756,125,

Filed: January 9, 2001

Examiner: F. VanderVegt

Art Unit: 1644

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the outstanding Office Action mailed on March 20, 2001, please amend the application as follows:

In the Specification:

Please amend the specification by rewriting the paragraph at page 6, lines 19-29 as follows:

Examples of such antibodies which are IL-6 antibodies include MH166 (Matsuda et al., Eur. J. Immunol. 18:951-956, 1988) and SK2 antibody (Sato et al., Journal for the 21st General Meeting of the Japan Immunology Association, 21:116, 1991). Examples of IL-6R antibodies include PM-1 antibody (deposited on July 12, 1989 at the Patent and Bio-Resource Center, National Institute of Advanced Industrial Science and Technology, Chuo No. 6, 1-1, Higashi 1 chome Tsukuba-shi, Ibaraki-ken 305-5466, Japan, as FERM BP-2998) (Hirata et al., J. Immunol. 143:2900-2906, 1989), AUK12-20 antibody, AUK64-7 antibody and AUK146-15 antibody (Intl. Unexamined Patent Application No. WO92-19759). An example of gp130 antibody is AM64 antibody (Japanese Unexamined Patent Publication 3-219894).

RECH CENTER 160072900

SEP 25 2001

RECEIVED